secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2026-02-02T23:59:59+00:00
Accession:  0001641489-26-000002
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv expands HPP737 license to worldwide; Newsoara pays $20M upfront, up to $115M milestones plus royalties
--------------------------------------------------------------------------------

- Second Amendment grants Newsoara global rights to PDE4 inhibitor HPP737 upon $20M upfront payment.
- Up to $50M in development milestones and $65M in sales-based milestones; royalties mid-single digits.
- Prior amendment became null and void in June 2025; this replaces it.
- Agreement with Newsoara Biopharma Co., Ltd., a Chinese partner.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148926000002/0001641489-26-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148926000002/vtvt-20260130.htm
  HTML page:      https://secwatch.observer/filing/0001641489-26-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer